Information Technology and Telemedicine Services in Community Oncology Practices.


Journal

JCO clinical cancer informatics
ISSN: 2473-4276
Titre abrégé: JCO Clin Cancer Inform
Pays: United States
ID NLM: 101708809

Informations de publication

Date de publication:
08 2023
Historique:
pmc-release: 04 08 2024
medline: 7 8 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

We described information technology support and use of telemedicine for cancer care and research purposes at community oncology practices within the National Cancer Institute Community Oncology Research Program (NCORP). We used data from the NCORP 2017 and 2022 Landscape Assessments. Separate logistic regression models were used to assess factors associated with the use of telemedicine for delivery of cancer care in 2017 and for research purposes in 2022 (cancer care delivery not assessed in 2022). Information was available from 210 and 259 practice groups excluding pediatric-only groups in 2017 and 2022, respectively. In 2017, 30% of practice groups used telemedicine for delivery of cancer care; half of these (15% overall) could use telemedicine for research purposes. In 2022, telemedicine was used for research purposes in 73% of practice groups. In multivariable models, self-identifying as a safety-net hospital was associated with a lower odd of telemedicine use for delivery of cancer care (adjusted odds ratio [AOR], 0.39; 95% CI, 0.17 to 0.93), whereas affiliation with a designated critical access hospital was associated with a higher odd of telemedicine use for delivery of cancer care (AOR, 2.29; 95% CI, 1.10 to 4.76). Having a general survivorship clinic (AOR, 1.92; 95% CI, 1.04 to 3.54) and number of oncology providers (increase per 10 providers; AOR, 1.32; 95% CI, 1.05 to 1.65) were associated with telemedicine use for research purposes. Almost one third of NCORP practice groups used telemedicine for cancer care delivery in 2017. In 2022, there is high capacity among NCORP practices (almost three-quarters) to use telemedicine for research purposes, especially among practices with a general survivorship clinic and a greater provider number.

Identifiants

pubmed: 37540817
doi: 10.1200/CCI.23.00086
pmc: PMC10569779
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2300086

Subventions

Organisme : NIA NIH HHS
ID : K24 AG056589
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189961
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG073985
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA237744
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189824
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA102618
Pays : United States

Références

Cancer Med. 2022 Feb;11(4):1192-1201
pubmed: 34989148
Clin Cancer Res. 2021 Feb 15;27(4):933-936
pubmed: 33229457
Fam Med Community Health. 2020 Aug;8(3):
pubmed: 32816942
Future Oncol. 2021 Aug;17(23):3077-3085
pubmed: 34102878
J Telemed Telecare. 2022 May 16;:1357633X221094215
pubmed: 35578537
Contemp Clin Trials Commun. 2016 Aug 15;3:74-79
pubmed: 27822565
Curr Cardiovasc Risk Rep. 2021;15(12):23
pubmed: 34900074
N Engl J Med. 2018 Jan 11;378(2):104-106
pubmed: 29320653
Front Oncol. 2020 Jun 26;10:1183
pubmed: 32676459
Health Informatics J. 2022 Jan-Mar;28(1):14604582221075561
pubmed: 35175881
JCO Oncol Pract. 2021 Sep;17(9):546-564
pubmed: 34319760
Telemed J E Health. 2020 May;26(5):603-613
pubmed: 31313977
JAMA Surg. 2021 Aug 1;156(8):703-704
pubmed: 33769441
Oncologist. 2020 Dec;25(12):1032-1038
pubmed: 32820842
J Am Coll Radiol. 2019 Apr;16(4 Pt A):427-434
pubmed: 30819455
J Hand Surg Am. 2017 Jun;42(6):411-416
pubmed: 28578767
Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):669-675
pubmed: 33355237
Patient Saf Surg. 2015 May 23;9:21
pubmed: 26136830
Ann Surg Oncol. 2021 Feb;28(2):632-638
pubmed: 32712893
Am Soc Clin Oncol Educ Book. 2018 May 23;38:540-545
pubmed: 30231354
Conn Med. 2014 Aug;78(7):425-7
pubmed: 25195309
Perspect Health Inf Manag. 2011 Jan 01;8:1f
pubmed: 21307989
J Am Med Inform Assoc. 2022 Apr 13;29(5):970-982
pubmed: 35150266

Auteurs

Kah Poh Loh (KP)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.

Ying Wang (Y)

Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY.

Sule Yilmaz (S)

Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.

Chandylen L Nightingale (CL)

Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston Salem, NC.

Susan K Parsons (SK)

Departments of Medicine and Pediatrics, Tufts University School of Medicine, Boston, MA.
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.

Christa Braun-Inglis (C)

University of Hawaii Cancer Center/Hawaii Minority/Underserved NCORP, Honolulu, HI.

Umang Gada (U)

Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.

Alexander Montes (A)

Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.

Allison Magnuson (A)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.

Eva Culakova (E)

Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.

Sarah Strause (S)

Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.

Charles Kamen (C)

Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.

Emily Dressler (E)

Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston Salem, NC.

Karen Mustian (K)

Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.

Gary Morrow (G)

Department of Surgery, Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.

Supriya Mohile (S)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH